Medical Care
Global Constrained Peptide Drugs Market Research Report 2025
- Apr 07, 25
- ID: 167493
- Pages: 87
- Figures: 83
- Views: 41
The global market for Constrained Peptide Drugs was valued at US$ 406 million in the year 2024 and is projected to reach a revised size of US$ 619 million by 2031, growing at a CAGR of 6.3% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Constrained Peptide Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Constrained Peptide Drugs.
The Constrained Peptide Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Constrained Peptide Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Constrained Peptide Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Aileron Therapeutics, Inc
Bicycle Therapeutics, PLC
Polyphor Limited
Protagonist Therapeutics, Inc
Santhera Pharmaceuticals Holding
Union Chimique Belge S.A. (UCB)
Pepscan Therapeutics B.V.
Pepticom Ltd.
PeptiDream, Inc.
CPC Scientific Inc.
Creative Peptides
Bio-Synthesis Inc
Segment by Type
Cyclic Peptides
Disulfide-Rich Peptides (DRPs)
Segment by Application
Hospital
Institute of Biology
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Constrained Peptide Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Constrained Peptide Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Constrained Peptide Drugs.
The Constrained Peptide Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Constrained Peptide Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Constrained Peptide Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Aileron Therapeutics, Inc
Bicycle Therapeutics, PLC
Polyphor Limited
Protagonist Therapeutics, Inc
Santhera Pharmaceuticals Holding
Union Chimique Belge S.A. (UCB)
Pepscan Therapeutics B.V.
Pepticom Ltd.
PeptiDream, Inc.
CPC Scientific Inc.
Creative Peptides
Bio-Synthesis Inc
Segment by Type
Cyclic Peptides
Disulfide-Rich Peptides (DRPs)
Segment by Application
Hospital
Institute of Biology
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Constrained Peptide Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Constrained Peptide Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Cyclic Peptides
1.2.3 Disulfide-Rich Peptides (DRPs)
1.3 Market by Application
1.3.1 Global Constrained Peptide Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Institute of Biology
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Constrained Peptide Drugs Market Perspective (2020-2031)
2.2 Global Constrained Peptide Drugs Growth Trends by Region
2.2.1 Global Constrained Peptide Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Constrained Peptide Drugs Historic Market Size by Region (2020-2025)
2.2.3 Constrained Peptide Drugs Forecasted Market Size by Region (2026-2031)
2.3 Constrained Peptide Drugs Market Dynamics
2.3.1 Constrained Peptide Drugs Industry Trends
2.3.2 Constrained Peptide Drugs Market Drivers
2.3.3 Constrained Peptide Drugs Market Challenges
2.3.4 Constrained Peptide Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Constrained Peptide Drugs Players by Revenue
3.1.1 Global Top Constrained Peptide Drugs Players by Revenue (2020-2025)
3.1.2 Global Constrained Peptide Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Constrained Peptide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Constrained Peptide Drugs Revenue
3.4 Global Constrained Peptide Drugs Market Concentration Ratio
3.4.1 Global Constrained Peptide Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Constrained Peptide Drugs Revenue in 2024
3.5 Global Key Players of Constrained Peptide Drugs Head office and Area Served
3.6 Global Key Players of Constrained Peptide Drugs, Product and Application
3.7 Global Key Players of Constrained Peptide Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Constrained Peptide Drugs Breakdown Data by Type
4.1 Global Constrained Peptide Drugs Historic Market Size by Type (2020-2025)
4.2 Global Constrained Peptide Drugs Forecasted Market Size by Type (2026-2031)
5 Constrained Peptide Drugs Breakdown Data by Application
5.1 Global Constrained Peptide Drugs Historic Market Size by Application (2020-2025)
5.2 Global Constrained Peptide Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Constrained Peptide Drugs Market Size (2020-2031)
6.2 North America Constrained Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Constrained Peptide Drugs Market Size by Country (2020-2025)
6.4 North America Constrained Peptide Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Constrained Peptide Drugs Market Size (2020-2031)
7.2 Europe Constrained Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Constrained Peptide Drugs Market Size by Country (2020-2025)
7.4 Europe Constrained Peptide Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Constrained Peptide Drugs Market Size (2020-2031)
8.2 Asia-Pacific Constrained Peptide Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Constrained Peptide Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Constrained Peptide Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Constrained Peptide Drugs Market Size (2020-2031)
9.2 Latin America Constrained Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Constrained Peptide Drugs Market Size by Country (2020-2025)
9.4 Latin America Constrained Peptide Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Constrained Peptide Drugs Market Size (2020-2031)
10.2 Middle East & Africa Constrained Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Constrained Peptide Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Constrained Peptide Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Aileron Therapeutics, Inc
11.1.1 Aileron Therapeutics, Inc Company Details
11.1.2 Aileron Therapeutics, Inc Business Overview
11.1.3 Aileron Therapeutics, Inc Constrained Peptide Drugs Introduction
11.1.4 Aileron Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2020-2025)
11.1.5 Aileron Therapeutics, Inc Recent Development
11.2 Bicycle Therapeutics, PLC
11.2.1 Bicycle Therapeutics, PLC Company Details
11.2.2 Bicycle Therapeutics, PLC Business Overview
11.2.3 Bicycle Therapeutics, PLC Constrained Peptide Drugs Introduction
11.2.4 Bicycle Therapeutics, PLC Revenue in Constrained Peptide Drugs Business (2020-2025)
11.2.5 Bicycle Therapeutics, PLC Recent Development
11.3 Polyphor Limited
11.3.1 Polyphor Limited Company Details
11.3.2 Polyphor Limited Business Overview
11.3.3 Polyphor Limited Constrained Peptide Drugs Introduction
11.3.4 Polyphor Limited Revenue in Constrained Peptide Drugs Business (2020-2025)
11.3.5 Polyphor Limited Recent Development
11.4 Protagonist Therapeutics, Inc
11.4.1 Protagonist Therapeutics, Inc Company Details
11.4.2 Protagonist Therapeutics, Inc Business Overview
11.4.3 Protagonist Therapeutics, Inc Constrained Peptide Drugs Introduction
11.4.4 Protagonist Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2020-2025)
11.4.5 Protagonist Therapeutics, Inc Recent Development
11.5 Santhera Pharmaceuticals Holding
11.5.1 Santhera Pharmaceuticals Holding Company Details
11.5.2 Santhera Pharmaceuticals Holding Business Overview
11.5.3 Santhera Pharmaceuticals Holding Constrained Peptide Drugs Introduction
11.5.4 Santhera Pharmaceuticals Holding Revenue in Constrained Peptide Drugs Business (2020-2025)
11.5.5 Santhera Pharmaceuticals Holding Recent Development
11.6 Union Chimique Belge S.A. (UCB)
11.6.1 Union Chimique Belge S.A. (UCB) Company Details
11.6.2 Union Chimique Belge S.A. (UCB) Business Overview
11.6.3 Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Introduction
11.6.4 Union Chimique Belge S.A. (UCB) Revenue in Constrained Peptide Drugs Business (2020-2025)
11.6.5 Union Chimique Belge S.A. (UCB) Recent Development
11.7 Pepscan Therapeutics B.V.
11.7.1 Pepscan Therapeutics B.V. Company Details
11.7.2 Pepscan Therapeutics B.V. Business Overview
11.7.3 Pepscan Therapeutics B.V. Constrained Peptide Drugs Introduction
11.7.4 Pepscan Therapeutics B.V. Revenue in Constrained Peptide Drugs Business (2020-2025)
11.7.5 Pepscan Therapeutics B.V. Recent Development
11.8 Pepticom Ltd.
11.8.1 Pepticom Ltd. Company Details
11.8.2 Pepticom Ltd. Business Overview
11.8.3 Pepticom Ltd. Constrained Peptide Drugs Introduction
11.8.4 Pepticom Ltd. Revenue in Constrained Peptide Drugs Business (2020-2025)
11.8.5 Pepticom Ltd. Recent Development
11.9 PeptiDream, Inc.
11.9.1 PeptiDream, Inc. Company Details
11.9.2 PeptiDream, Inc. Business Overview
11.9.3 PeptiDream, Inc. Constrained Peptide Drugs Introduction
11.9.4 PeptiDream, Inc. Revenue in Constrained Peptide Drugs Business (2020-2025)
11.9.5 PeptiDream, Inc. Recent Development
11.10 CPC Scientific Inc.
11.10.1 CPC Scientific Inc. Company Details
11.10.2 CPC Scientific Inc. Business Overview
11.10.3 CPC Scientific Inc. Constrained Peptide Drugs Introduction
11.10.4 CPC Scientific Inc. Revenue in Constrained Peptide Drugs Business (2020-2025)
11.10.5 CPC Scientific Inc. Recent Development
11.11 Creative Peptides
11.11.1 Creative Peptides Company Details
11.11.2 Creative Peptides Business Overview
11.11.3 Creative Peptides Constrained Peptide Drugs Introduction
11.11.4 Creative Peptides Revenue in Constrained Peptide Drugs Business (2020-2025)
11.11.5 Creative Peptides Recent Development
11.12 Bio-Synthesis Inc
11.12.1 Bio-Synthesis Inc Company Details
11.12.2 Bio-Synthesis Inc Business Overview
11.12.3 Bio-Synthesis Inc Constrained Peptide Drugs Introduction
11.12.4 Bio-Synthesis Inc Revenue in Constrained Peptide Drugs Business (2020-2025)
11.12.5 Bio-Synthesis Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Constrained Peptide Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Cyclic Peptides
1.2.3 Disulfide-Rich Peptides (DRPs)
1.3 Market by Application
1.3.1 Global Constrained Peptide Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Institute of Biology
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Constrained Peptide Drugs Market Perspective (2020-2031)
2.2 Global Constrained Peptide Drugs Growth Trends by Region
2.2.1 Global Constrained Peptide Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Constrained Peptide Drugs Historic Market Size by Region (2020-2025)
2.2.3 Constrained Peptide Drugs Forecasted Market Size by Region (2026-2031)
2.3 Constrained Peptide Drugs Market Dynamics
2.3.1 Constrained Peptide Drugs Industry Trends
2.3.2 Constrained Peptide Drugs Market Drivers
2.3.3 Constrained Peptide Drugs Market Challenges
2.3.4 Constrained Peptide Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Constrained Peptide Drugs Players by Revenue
3.1.1 Global Top Constrained Peptide Drugs Players by Revenue (2020-2025)
3.1.2 Global Constrained Peptide Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Constrained Peptide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Constrained Peptide Drugs Revenue
3.4 Global Constrained Peptide Drugs Market Concentration Ratio
3.4.1 Global Constrained Peptide Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Constrained Peptide Drugs Revenue in 2024
3.5 Global Key Players of Constrained Peptide Drugs Head office and Area Served
3.6 Global Key Players of Constrained Peptide Drugs, Product and Application
3.7 Global Key Players of Constrained Peptide Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Constrained Peptide Drugs Breakdown Data by Type
4.1 Global Constrained Peptide Drugs Historic Market Size by Type (2020-2025)
4.2 Global Constrained Peptide Drugs Forecasted Market Size by Type (2026-2031)
5 Constrained Peptide Drugs Breakdown Data by Application
5.1 Global Constrained Peptide Drugs Historic Market Size by Application (2020-2025)
5.2 Global Constrained Peptide Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Constrained Peptide Drugs Market Size (2020-2031)
6.2 North America Constrained Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Constrained Peptide Drugs Market Size by Country (2020-2025)
6.4 North America Constrained Peptide Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Constrained Peptide Drugs Market Size (2020-2031)
7.2 Europe Constrained Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Constrained Peptide Drugs Market Size by Country (2020-2025)
7.4 Europe Constrained Peptide Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Constrained Peptide Drugs Market Size (2020-2031)
8.2 Asia-Pacific Constrained Peptide Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Constrained Peptide Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Constrained Peptide Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Constrained Peptide Drugs Market Size (2020-2031)
9.2 Latin America Constrained Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Constrained Peptide Drugs Market Size by Country (2020-2025)
9.4 Latin America Constrained Peptide Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Constrained Peptide Drugs Market Size (2020-2031)
10.2 Middle East & Africa Constrained Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Constrained Peptide Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Constrained Peptide Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Aileron Therapeutics, Inc
11.1.1 Aileron Therapeutics, Inc Company Details
11.1.2 Aileron Therapeutics, Inc Business Overview
11.1.3 Aileron Therapeutics, Inc Constrained Peptide Drugs Introduction
11.1.4 Aileron Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2020-2025)
11.1.5 Aileron Therapeutics, Inc Recent Development
11.2 Bicycle Therapeutics, PLC
11.2.1 Bicycle Therapeutics, PLC Company Details
11.2.2 Bicycle Therapeutics, PLC Business Overview
11.2.3 Bicycle Therapeutics, PLC Constrained Peptide Drugs Introduction
11.2.4 Bicycle Therapeutics, PLC Revenue in Constrained Peptide Drugs Business (2020-2025)
11.2.5 Bicycle Therapeutics, PLC Recent Development
11.3 Polyphor Limited
11.3.1 Polyphor Limited Company Details
11.3.2 Polyphor Limited Business Overview
11.3.3 Polyphor Limited Constrained Peptide Drugs Introduction
11.3.4 Polyphor Limited Revenue in Constrained Peptide Drugs Business (2020-2025)
11.3.5 Polyphor Limited Recent Development
11.4 Protagonist Therapeutics, Inc
11.4.1 Protagonist Therapeutics, Inc Company Details
11.4.2 Protagonist Therapeutics, Inc Business Overview
11.4.3 Protagonist Therapeutics, Inc Constrained Peptide Drugs Introduction
11.4.4 Protagonist Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2020-2025)
11.4.5 Protagonist Therapeutics, Inc Recent Development
11.5 Santhera Pharmaceuticals Holding
11.5.1 Santhera Pharmaceuticals Holding Company Details
11.5.2 Santhera Pharmaceuticals Holding Business Overview
11.5.3 Santhera Pharmaceuticals Holding Constrained Peptide Drugs Introduction
11.5.4 Santhera Pharmaceuticals Holding Revenue in Constrained Peptide Drugs Business (2020-2025)
11.5.5 Santhera Pharmaceuticals Holding Recent Development
11.6 Union Chimique Belge S.A. (UCB)
11.6.1 Union Chimique Belge S.A. (UCB) Company Details
11.6.2 Union Chimique Belge S.A. (UCB) Business Overview
11.6.3 Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Introduction
11.6.4 Union Chimique Belge S.A. (UCB) Revenue in Constrained Peptide Drugs Business (2020-2025)
11.6.5 Union Chimique Belge S.A. (UCB) Recent Development
11.7 Pepscan Therapeutics B.V.
11.7.1 Pepscan Therapeutics B.V. Company Details
11.7.2 Pepscan Therapeutics B.V. Business Overview
11.7.3 Pepscan Therapeutics B.V. Constrained Peptide Drugs Introduction
11.7.4 Pepscan Therapeutics B.V. Revenue in Constrained Peptide Drugs Business (2020-2025)
11.7.5 Pepscan Therapeutics B.V. Recent Development
11.8 Pepticom Ltd.
11.8.1 Pepticom Ltd. Company Details
11.8.2 Pepticom Ltd. Business Overview
11.8.3 Pepticom Ltd. Constrained Peptide Drugs Introduction
11.8.4 Pepticom Ltd. Revenue in Constrained Peptide Drugs Business (2020-2025)
11.8.5 Pepticom Ltd. Recent Development
11.9 PeptiDream, Inc.
11.9.1 PeptiDream, Inc. Company Details
11.9.2 PeptiDream, Inc. Business Overview
11.9.3 PeptiDream, Inc. Constrained Peptide Drugs Introduction
11.9.4 PeptiDream, Inc. Revenue in Constrained Peptide Drugs Business (2020-2025)
11.9.5 PeptiDream, Inc. Recent Development
11.10 CPC Scientific Inc.
11.10.1 CPC Scientific Inc. Company Details
11.10.2 CPC Scientific Inc. Business Overview
11.10.3 CPC Scientific Inc. Constrained Peptide Drugs Introduction
11.10.4 CPC Scientific Inc. Revenue in Constrained Peptide Drugs Business (2020-2025)
11.10.5 CPC Scientific Inc. Recent Development
11.11 Creative Peptides
11.11.1 Creative Peptides Company Details
11.11.2 Creative Peptides Business Overview
11.11.3 Creative Peptides Constrained Peptide Drugs Introduction
11.11.4 Creative Peptides Revenue in Constrained Peptide Drugs Business (2020-2025)
11.11.5 Creative Peptides Recent Development
11.12 Bio-Synthesis Inc
11.12.1 Bio-Synthesis Inc Company Details
11.12.2 Bio-Synthesis Inc Business Overview
11.12.3 Bio-Synthesis Inc Constrained Peptide Drugs Introduction
11.12.4 Bio-Synthesis Inc Revenue in Constrained Peptide Drugs Business (2020-2025)
11.12.5 Bio-Synthesis Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Constrained Peptide Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Cyclic Peptides
Table 3. Key Players of Disulfide-Rich Peptides (DRPs)
Table 4. Global Constrained Peptide Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Constrained Peptide Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Constrained Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Constrained Peptide Drugs Market Share by Region (2020-2025)
Table 8. Global Constrained Peptide Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Constrained Peptide Drugs Market Share by Region (2026-2031)
Table 10. Constrained Peptide Drugs Market Trends
Table 11. Constrained Peptide Drugs Market Drivers
Table 12. Constrained Peptide Drugs Market Challenges
Table 13. Constrained Peptide Drugs Market Restraints
Table 14. Global Constrained Peptide Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Constrained Peptide Drugs Market Share by Players (2020-2025)
Table 16. Global Top Constrained Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Constrained Peptide Drugs as of 2024)
Table 17. Ranking of Global Top Constrained Peptide Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Constrained Peptide Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Constrained Peptide Drugs, Headquarters and Area Served
Table 20. Global Key Players of Constrained Peptide Drugs, Product and Application
Table 21. Global Key Players of Constrained Peptide Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Constrained Peptide Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Constrained Peptide Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global Constrained Peptide Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Constrained Peptide Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global Constrained Peptide Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Constrained Peptide Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global Constrained Peptide Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Constrained Peptide Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America Constrained Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Constrained Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Constrained Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Constrained Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Constrained Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Constrained Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Constrained Peptide Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Constrained Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Constrained Peptide Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Constrained Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Constrained Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Constrained Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Constrained Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Constrained Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Constrained Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Aileron Therapeutics, Inc Company Details
Table 47. Aileron Therapeutics, Inc Business Overview
Table 48. Aileron Therapeutics, Inc Constrained Peptide Drugs Product
Table 49. Aileron Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 50. Aileron Therapeutics, Inc Recent Development
Table 51. Bicycle Therapeutics, PLC Company Details
Table 52. Bicycle Therapeutics, PLC Business Overview
Table 53. Bicycle Therapeutics, PLC Constrained Peptide Drugs Product
Table 54. Bicycle Therapeutics, PLC Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 55. Bicycle Therapeutics, PLC Recent Development
Table 56. Polyphor Limited Company Details
Table 57. Polyphor Limited Business Overview
Table 58. Polyphor Limited Constrained Peptide Drugs Product
Table 59. Polyphor Limited Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 60. Polyphor Limited Recent Development
Table 61. Protagonist Therapeutics, Inc Company Details
Table 62. Protagonist Therapeutics, Inc Business Overview
Table 63. Protagonist Therapeutics, Inc Constrained Peptide Drugs Product
Table 64. Protagonist Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 65. Protagonist Therapeutics, Inc Recent Development
Table 66. Santhera Pharmaceuticals Holding Company Details
Table 67. Santhera Pharmaceuticals Holding Business Overview
Table 68. Santhera Pharmaceuticals Holding Constrained Peptide Drugs Product
Table 69. Santhera Pharmaceuticals Holding Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 70. Santhera Pharmaceuticals Holding Recent Development
Table 71. Union Chimique Belge S.A. (UCB) Company Details
Table 72. Union Chimique Belge S.A. (UCB) Business Overview
Table 73. Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Product
Table 74. Union Chimique Belge S.A. (UCB) Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 75. Union Chimique Belge S.A. (UCB) Recent Development
Table 76. Pepscan Therapeutics B.V. Company Details
Table 77. Pepscan Therapeutics B.V. Business Overview
Table 78. Pepscan Therapeutics B.V. Constrained Peptide Drugs Product
Table 79. Pepscan Therapeutics B.V. Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 80. Pepscan Therapeutics B.V. Recent Development
Table 81. Pepticom Ltd. Company Details
Table 82. Pepticom Ltd. Business Overview
Table 83. Pepticom Ltd. Constrained Peptide Drugs Product
Table 84. Pepticom Ltd. Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 85. Pepticom Ltd. Recent Development
Table 86. PeptiDream, Inc. Company Details
Table 87. PeptiDream, Inc. Business Overview
Table 88. PeptiDream, Inc. Constrained Peptide Drugs Product
Table 89. PeptiDream, Inc. Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 90. PeptiDream, Inc. Recent Development
Table 91. CPC Scientific Inc. Company Details
Table 92. CPC Scientific Inc. Business Overview
Table 93. CPC Scientific Inc. Constrained Peptide Drugs Product
Table 94. CPC Scientific Inc. Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 95. CPC Scientific Inc. Recent Development
Table 96. Creative Peptides Company Details
Table 97. Creative Peptides Business Overview
Table 98. Creative Peptides Constrained Peptide Drugs Product
Table 99. Creative Peptides Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 100. Creative Peptides Recent Development
Table 101. Bio-Synthesis Inc Company Details
Table 102. Bio-Synthesis Inc Business Overview
Table 103. Bio-Synthesis Inc Constrained Peptide Drugs Product
Table 104. Bio-Synthesis Inc Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 105. Bio-Synthesis Inc Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
Table 109. Authors List of This Report
List of Figures
Figure 1. Constrained Peptide Drugs Picture
Figure 2. Global Constrained Peptide Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Constrained Peptide Drugs Market Share by Type: 2024 VS 2031
Figure 4. Cyclic Peptides Features
Figure 5. Disulfide-Rich Peptides (DRPs) Features
Figure 6. Global Constrained Peptide Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Constrained Peptide Drugs Market Share by Application: 2024 VS 2031
Figure 8. Hospital Case Studies
Figure 9. Institute of Biology Case Studies
Figure 10. Others Case Studies
Figure 11. Constrained Peptide Drugs Report Years Considered
Figure 12. Global Constrained Peptide Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Constrained Peptide Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Constrained Peptide Drugs Market Share by Region: 2024 VS 2031
Figure 15. Global Constrained Peptide Drugs Market Share by Players in 2024
Figure 16. Global Top Constrained Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Constrained Peptide Drugs as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Constrained Peptide Drugs Revenue in 2024
Figure 18. North America Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Constrained Peptide Drugs Market Share by Country (2020-2031)
Figure 20. United States Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Constrained Peptide Drugs Market Share by Country (2020-2031)
Figure 24. Germany Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Constrained Peptide Drugs Market Share by Region (2020-2031)
Figure 32. China Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Constrained Peptide Drugs Market Share by Country (2020-2031)
Figure 40. Mexico Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Constrained Peptide Drugs Market Share by Country (2020-2031)
Figure 44. Turkey Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Aileron Therapeutics, Inc Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 48. Bicycle Therapeutics, PLC Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 49. Polyphor Limited Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 50. Protagonist Therapeutics, Inc Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 51. Santhera Pharmaceuticals Holding Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 52. Union Chimique Belge S.A. (UCB) Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 53. Pepscan Therapeutics B.V. Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 54. Pepticom Ltd. Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 55. PeptiDream, Inc. Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 56. CPC Scientific Inc. Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 57. Creative Peptides Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 58. Bio-Synthesis Inc Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Table 1. Global Constrained Peptide Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Cyclic Peptides
Table 3. Key Players of Disulfide-Rich Peptides (DRPs)
Table 4. Global Constrained Peptide Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Constrained Peptide Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Constrained Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Constrained Peptide Drugs Market Share by Region (2020-2025)
Table 8. Global Constrained Peptide Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Constrained Peptide Drugs Market Share by Region (2026-2031)
Table 10. Constrained Peptide Drugs Market Trends
Table 11. Constrained Peptide Drugs Market Drivers
Table 12. Constrained Peptide Drugs Market Challenges
Table 13. Constrained Peptide Drugs Market Restraints
Table 14. Global Constrained Peptide Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Constrained Peptide Drugs Market Share by Players (2020-2025)
Table 16. Global Top Constrained Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Constrained Peptide Drugs as of 2024)
Table 17. Ranking of Global Top Constrained Peptide Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Constrained Peptide Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Constrained Peptide Drugs, Headquarters and Area Served
Table 20. Global Key Players of Constrained Peptide Drugs, Product and Application
Table 21. Global Key Players of Constrained Peptide Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Constrained Peptide Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Constrained Peptide Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global Constrained Peptide Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Constrained Peptide Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global Constrained Peptide Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Constrained Peptide Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global Constrained Peptide Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Constrained Peptide Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America Constrained Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Constrained Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Constrained Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Constrained Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Constrained Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Constrained Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Constrained Peptide Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Constrained Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Constrained Peptide Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Constrained Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Constrained Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Constrained Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Constrained Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Constrained Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Constrained Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Aileron Therapeutics, Inc Company Details
Table 47. Aileron Therapeutics, Inc Business Overview
Table 48. Aileron Therapeutics, Inc Constrained Peptide Drugs Product
Table 49. Aileron Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 50. Aileron Therapeutics, Inc Recent Development
Table 51. Bicycle Therapeutics, PLC Company Details
Table 52. Bicycle Therapeutics, PLC Business Overview
Table 53. Bicycle Therapeutics, PLC Constrained Peptide Drugs Product
Table 54. Bicycle Therapeutics, PLC Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 55. Bicycle Therapeutics, PLC Recent Development
Table 56. Polyphor Limited Company Details
Table 57. Polyphor Limited Business Overview
Table 58. Polyphor Limited Constrained Peptide Drugs Product
Table 59. Polyphor Limited Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 60. Polyphor Limited Recent Development
Table 61. Protagonist Therapeutics, Inc Company Details
Table 62. Protagonist Therapeutics, Inc Business Overview
Table 63. Protagonist Therapeutics, Inc Constrained Peptide Drugs Product
Table 64. Protagonist Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 65. Protagonist Therapeutics, Inc Recent Development
Table 66. Santhera Pharmaceuticals Holding Company Details
Table 67. Santhera Pharmaceuticals Holding Business Overview
Table 68. Santhera Pharmaceuticals Holding Constrained Peptide Drugs Product
Table 69. Santhera Pharmaceuticals Holding Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 70. Santhera Pharmaceuticals Holding Recent Development
Table 71. Union Chimique Belge S.A. (UCB) Company Details
Table 72. Union Chimique Belge S.A. (UCB) Business Overview
Table 73. Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Product
Table 74. Union Chimique Belge S.A. (UCB) Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 75. Union Chimique Belge S.A. (UCB) Recent Development
Table 76. Pepscan Therapeutics B.V. Company Details
Table 77. Pepscan Therapeutics B.V. Business Overview
Table 78. Pepscan Therapeutics B.V. Constrained Peptide Drugs Product
Table 79. Pepscan Therapeutics B.V. Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 80. Pepscan Therapeutics B.V. Recent Development
Table 81. Pepticom Ltd. Company Details
Table 82. Pepticom Ltd. Business Overview
Table 83. Pepticom Ltd. Constrained Peptide Drugs Product
Table 84. Pepticom Ltd. Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 85. Pepticom Ltd. Recent Development
Table 86. PeptiDream, Inc. Company Details
Table 87. PeptiDream, Inc. Business Overview
Table 88. PeptiDream, Inc. Constrained Peptide Drugs Product
Table 89. PeptiDream, Inc. Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 90. PeptiDream, Inc. Recent Development
Table 91. CPC Scientific Inc. Company Details
Table 92. CPC Scientific Inc. Business Overview
Table 93. CPC Scientific Inc. Constrained Peptide Drugs Product
Table 94. CPC Scientific Inc. Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 95. CPC Scientific Inc. Recent Development
Table 96. Creative Peptides Company Details
Table 97. Creative Peptides Business Overview
Table 98. Creative Peptides Constrained Peptide Drugs Product
Table 99. Creative Peptides Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 100. Creative Peptides Recent Development
Table 101. Bio-Synthesis Inc Company Details
Table 102. Bio-Synthesis Inc Business Overview
Table 103. Bio-Synthesis Inc Constrained Peptide Drugs Product
Table 104. Bio-Synthesis Inc Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)
Table 105. Bio-Synthesis Inc Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
Table 109. Authors List of This Report
List of Figures
Figure 1. Constrained Peptide Drugs Picture
Figure 2. Global Constrained Peptide Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Constrained Peptide Drugs Market Share by Type: 2024 VS 2031
Figure 4. Cyclic Peptides Features
Figure 5. Disulfide-Rich Peptides (DRPs) Features
Figure 6. Global Constrained Peptide Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Constrained Peptide Drugs Market Share by Application: 2024 VS 2031
Figure 8. Hospital Case Studies
Figure 9. Institute of Biology Case Studies
Figure 10. Others Case Studies
Figure 11. Constrained Peptide Drugs Report Years Considered
Figure 12. Global Constrained Peptide Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Constrained Peptide Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Constrained Peptide Drugs Market Share by Region: 2024 VS 2031
Figure 15. Global Constrained Peptide Drugs Market Share by Players in 2024
Figure 16. Global Top Constrained Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Constrained Peptide Drugs as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Constrained Peptide Drugs Revenue in 2024
Figure 18. North America Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Constrained Peptide Drugs Market Share by Country (2020-2031)
Figure 20. United States Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Constrained Peptide Drugs Market Share by Country (2020-2031)
Figure 24. Germany Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Constrained Peptide Drugs Market Share by Region (2020-2031)
Figure 32. China Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Constrained Peptide Drugs Market Share by Country (2020-2031)
Figure 40. Mexico Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Constrained Peptide Drugs Market Share by Country (2020-2031)
Figure 44. Turkey Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Aileron Therapeutics, Inc Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 48. Bicycle Therapeutics, PLC Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 49. Polyphor Limited Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 50. Protagonist Therapeutics, Inc Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 51. Santhera Pharmaceuticals Holding Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 52. Union Chimique Belge S.A. (UCB) Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 53. Pepscan Therapeutics B.V. Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 54. Pepticom Ltd. Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 55. PeptiDream, Inc. Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 56. CPC Scientific Inc. Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 57. Creative Peptides Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 58. Bio-Synthesis Inc Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232